CN103153280B - 丙型肝炎病毒抑制剂的组合 - Google Patents

丙型肝炎病毒抑制剂的组合 Download PDF

Info

Publication number
CN103153280B
CN103153280B CN201180048188.1A CN201180048188A CN103153280B CN 103153280 B CN103153280 B CN 103153280B CN 201180048188 A CN201180048188 A CN 201180048188A CN 103153280 B CN103153280 B CN 103153280B
Authority
CN
China
Prior art keywords
hcv
compound
formula
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180048188.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103153280A (zh
Inventor
M.高
D.F.卡迪那
J.A.莱姆
F.麦克菲
S.A.沃斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to CN201510608270.5A priority Critical patent/CN105148275A/zh
Publication of CN103153280A publication Critical patent/CN103153280A/zh
Application granted granted Critical
Publication of CN103153280B publication Critical patent/CN103153280B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180048188.1A 2010-08-06 2011-08-02 丙型肝炎病毒抑制剂的组合 Expired - Fee Related CN103153280B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510608270.5A CN105148275A (zh) 2010-08-06 2011-08-02 丙型肝炎病毒抑制剂的组合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37139910P 2010-08-06 2010-08-06
US61/371,399 2010-08-06
PCT/US2011/046285 WO2012018829A1 (en) 2010-08-06 2011-08-02 Combinations of hepatitis c virus inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510608270.5A Division CN105148275A (zh) 2010-08-06 2011-08-02 丙型肝炎病毒抑制剂的组合

Publications (2)

Publication Number Publication Date
CN103153280A CN103153280A (zh) 2013-06-12
CN103153280B true CN103153280B (zh) 2015-09-09

Family

ID=45559795

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180048188.1A Expired - Fee Related CN103153280B (zh) 2010-08-06 2011-08-02 丙型肝炎病毒抑制剂的组合
CN201510608270.5A Pending CN105148275A (zh) 2010-08-06 2011-08-02 丙型肝炎病毒抑制剂的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510608270.5A Pending CN105148275A (zh) 2010-08-06 2011-08-02 丙型肝炎病毒抑制剂的组合

Country Status (14)

Country Link
US (3) US20120196794A1 (cg-RX-API-DMAC7.html)
EP (1) EP2600835B1 (cg-RX-API-DMAC7.html)
JP (2) JP6196154B2 (cg-RX-API-DMAC7.html)
KR (1) KR101846596B1 (cg-RX-API-DMAC7.html)
CN (2) CN103153280B (cg-RX-API-DMAC7.html)
AU (1) AU2011285890B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013002922A2 (cg-RX-API-DMAC7.html)
CA (1) CA2807589C (cg-RX-API-DMAC7.html)
EA (1) EA022303B1 (cg-RX-API-DMAC7.html)
ES (1) ES2685174T3 (cg-RX-API-DMAC7.html)
IL (1) IL224369B (cg-RX-API-DMAC7.html)
MX (1) MX2013001170A (cg-RX-API-DMAC7.html)
SG (2) SG187193A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012018829A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
EP2963034A1 (en) 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103842369A (zh) * 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2909205T (pt) 2012-10-19 2017-02-06 Bristol Myers Squibb Co Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102655873A (zh) * 2009-10-12 2012-09-05 百时美施贵宝公司 特异性hcv ns5a抑制剂与hcv ns3蛋白酶抑制剂的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2346329B1 (en) * 2008-10-09 2013-08-21 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102655873A (zh) * 2009-10-12 2012-09-05 百时美施贵宝公司 特异性hcv ns5a抑制剂与hcv ns3蛋白酶抑制剂的组合

Also Published As

Publication number Publication date
EA201390155A1 (ru) 2013-05-30
US20150335655A1 (en) 2015-11-26
JP6196154B2 (ja) 2017-09-13
SG187193A1 (en) 2013-03-28
US20140235617A1 (en) 2014-08-21
CA2807589C (en) 2016-08-30
JP2013535487A (ja) 2013-09-12
AU2011285890A1 (en) 2013-03-21
MX2013001170A (es) 2013-02-15
KR101846596B1 (ko) 2018-04-06
SG2014008346A (en) 2014-05-29
KR20140002611A (ko) 2014-01-08
WO2012018829A1 (en) 2012-02-09
ES2685174T3 (es) 2018-10-05
US20120196794A1 (en) 2012-08-02
EP2600835A1 (en) 2013-06-12
CA2807589A1 (en) 2012-02-09
JP2016155844A (ja) 2016-09-01
EA022303B1 (ru) 2015-12-30
CN103153280A (zh) 2013-06-12
AU2011285890B2 (en) 2014-12-18
CN105148275A (zh) 2015-12-16
EP2600835A4 (en) 2013-11-20
IL224369B (en) 2019-08-29
EP2600835B1 (en) 2018-05-30
BR112013002922A2 (pt) 2016-06-07

Similar Documents

Publication Publication Date Title
CN103153280B (zh) 丙型肝炎病毒抑制剂的组合
KR101755058B1 (ko) 특정 ｈｃｖ ｎｓ５ａ 억제제 및 ｈｃｖ ｎｓ３ 프로테아제 억제제의 조합물
US9060971B2 (en) Combination pharmaceutical agents as inhibitors of HCV replication
HK1180211B (en) Combinations of hepatitis c virus inhibitors
HK1180211A (en) Combinations of hepatitis c virus inhibitors
US20200330460A1 (en) Methods for Treating HCV
HK40004326A (en) Methods for treating hcv
HK1172237A (en) Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
HK1172237B (en) Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BRISTOL-MYERS SQUIBB IRELAND HOLDINGS LTD.

Free format text: FORMER OWNER: SQUIBB BRISTOL MYERS CO.

Effective date: 20150625

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150625

Address after: Swiss Stein Schoenberg

Applicant after: SQUIBB BRISTOL MYERS CO.

Address before: new jersey

Applicant before: Squibb Bristol Myers Co.

C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Swiss Stein Schoenberg

Patentee after: Bristol Myers Squibb Ireland Holdings Limited

Address before: Swiss Stein Schoenberg

Patentee before: SQUIBB BRISTOL MYERS CO.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190531

Address after: Swiss Stein Schoenberg

Patentee after: Bristol-Squibb Ireland Holdings Limited

Address before: Swiss Stein Schoenberg

Patentee before: Bristol Myers Squibb Ireland Holdings Limited

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Swiss Stein Schoenberg

Patentee after: Bristol-Squibb Holdings Ireland Infinite

Address before: Swiss Stein Schoenberg

Patentee before: Bristol-Squibb Ireland Holdings Limited

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150909

Termination date: 20200802